https://scholars.lib.ntu.edu.tw/handle/123456789/627123
標題: | Impact of the SARS-CoV-2 pandemic on the health of individuals with intoxication-type metabolic diseases-Data from the E-IMD consortium | 作者: | Mütze, Ulrike Gleich, Florian Barić, Ivo Baumgartner, Mathias Burlina, Alberto Chapman, Kimberly A YIN-HSIU CHIEN Cortès-Saladelafont, Elisenda De Laet, Corinne Dobbelaere, Dries Eysken, Francois Gautschi, Matthias Santer, Rene Häberle, Johannes Joaquín, Clara Karall, Daniela Lindner, Martin Lund, Allan M Mühlhausen, Chris Murphy, Elaine Roland, Dominique Ruiz Gomez, Angeles Skouma, Anastasia Grünert, Sarah C Wagenmakers, Margreet Garbade, Sven F Kölker, Stefan Boy, Nikolas |
關鍵字: | COVID-19; E-IMD; IMD; SARS-CoV-2; coronavirus; intoxication-type inherited metabolic diseases; pandemic; survey | 公開日期: | 20-十月-2022 | 出版社: | WILEY | 來源出版物: | Journal of inherited metabolic disease | 摘要: | The SARS-CoV-2 pandemic challenges healthcare systems worldwide. Within inherited metabolic disorders (IMDs) the vulnerable subgroup of intoxication-type IMDs such as organic acidurias (OA) and urea cycle disorders (UCD) show risk for infection-induced morbidity and mortality. This study (observation period February 2020 to December 2021) evaluates impact on medical health care as well as disease course and outcome of SARS-CoV-2 infections in patients with intoxication-type IMDs managed by participants of the European Registry and Network for intoxication type metabolic diseases Consortium (E-IMD). Survey's respondents managing 792 patients (n = 479 pediatric; n = 313 adult) with intoxication-type IMDs (n = 454 OA; n = 338 UCD) in 14 countries reported on 59 (OA: n = 36; UCD: n = 23), SARS-CoV-2 infections (7.4%). Medical services were increasingly requested (95%), mostly alleviated by remote technologies (86%). Problems with medical supply were scarce (5%). Regular follow-up visits were reduced in 41% (range 10%-50%). Most infected individuals (49/59; 83%) showed mild clinical symptoms, while 10 patients (17%; n = 6 OA including four transplanted MMA patients; n = 4 UCD) were hospitalized (metabolic decompensation in 30%). ICU treatment was not reported. Hospitalization rate did not differ for diagnosis or age group (p = 0.778). Survival rate was 100%. Full recovery was reported for 100% in outpatient care and 90% of hospitalized individuals. SARS-CoV-2 impacts health care of individuals with intoxication-type IMDs worldwide. Most infected individuals, however, showed mild symptoms and did not require hospitalization. SARS-CoV-2-induced metabolic decompensations were usually mild without increased risk for ICU treatment. Overall prognosis of infected individuals is very promising and IMD-specific or COVID-19-related complications have not been observed. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627123 | ISSN: | 0141-8955 | DOI: | 10.1002/jimd.12572 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。